# Explained: Why the ban on reusing single-use medical devices divides hospitals and makers

URL: https://upsc.help/current-affairs/2026-11-20/single-use-device-reuse-ban-explained/
Date: 20 November 2026 (2026-11-20)
Source: The Hindu, Page II
UPSC papers: GS2, GS3
Publisher: upsc.help (Pratidin), free and open-source UPSC Civil Services current affairs. Not affiliated with UPSC. Every fact was checked against the source reports by a separate review before publishing.

**In one line:** The DGHS has told all hospitals to stop reusing devices labelled single-use, citing infection risks and overcharging, while hospitals warn of higher costs and want regulated reuse.

On 16 October 2026, the Directorate General of Health Services (DGHS), under the Union Health Ministry, wrote to State and Union Territory health secretaries and directors of health services, the Drugs Controller General of India and State drug controllers, prohibiting the reuse of single-use medical devices and disposable surgical items in all public and private health facilities. Facilities must use them strictly as the original manufacturer instructs. The letter said such items were being sterilised and reused in some private and corporate hospitals, particularly in cardiology, nephrology, oncology, cardiothoracic and vascular surgery, and neurosurgery, and that patients or government authorities were sometimes charged the full price. It cited the Drugs and Cosmetics Act, 1940, the Medical Devices Rules, 2017 and the Clinical Establishments Act, 2010, and asked States to inspect and act. The Hindu's explainer of 20 November examines who decides what is safe to reuse.

The DGHS cited cross-infection, device malfunction, loss of performance and procedure-related complications. Devices reported as reused include cardiac, balloon and ablation catheters, guidewires, dialysers and blood tubing, surgical staplers, laparoscopic trocars, orthopaedic drill bits, syringes and needles. Device makers' bodies AiMeD and MTaI welcomed the ban; AiMeD said single-use devices are not necessarily designed or validated for repeated use and that manufacturers should not be liable when devices are reused against their instructions. Hospital chains and associations including AHPI and NATHEALTH sought a rethink, saying costs of complex procedures could rise by 25% to 75%. They cited industry estimates that over 60% of dialysis sessions use multiple-use dialysers, about 40 million treatments a year for about 5 lakh patients, and noted that the Pradhan Mantri National Dialysis Programme allows a dialyser's reuse for the same patient under set conditions.

The explainer argues that manufacturers, who decide which devices are 'single-use', gain from new purchases, and that India lacks consistent reprocessing protocols, tracking and records. It notes that the US Food and Drug Administration regulates reprocessors with the same requirements as original manufacturers, and that Canada, Japan and the European Union also have frameworks. Safe reprocessing needs validated cleaning, integrity checks, performance standards and quality control, not just sterilisation. Suggested steps include a national classification of devices by reusability, reprocessing only in approved facilities with validated methods, and more domestic manufacturing to lower costs. Hospital groups have asked for a three to six month transition and a regulated reuse framework with audits, patient consent, transparent billing and traceability.

## Prelims facts

- On 16 October 2026 the DGHS prohibited reuse of single-use medical devices and disposable surgical items in all public and private health facilities.
- The letter cites the Drugs and Cosmetics Act, 1940, the Medical Devices Rules, 2017 and the Clinical Establishments Act, 2010.
- Hospital groups say costs of complex procedures could rise 25% to 75% and that over 60% of dialysis sessions use multiple-use dialysers.
- Device makers' bodies AiMeD and MTaI support the ban; AiMeD says manufacturers should not be liable when devices are reused against their instructions.
- The US FDA treats reprocessors of single-use devices as manufacturers, an example of regulated reprocessing India lacks.

## Quick recall

- **Which body banned reuse of single-use medical devices on 16 October 2026?** The Directorate General of Health Services (DGHS), Union Health Ministry.
- **Under which Act are the Medical Devices Rules, 2017 made?** The Drugs and Cosmetics Act, 1940.
- **How many risk classes do the Medical Devices Rules, 2017 use?** Four: A (low), B (low to moderate), C (moderate to high), D (high).
- **Which body is India's central regulator of medical devices?** The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.
- **Rise in costs of complex procedures feared by hospital groups?** 25% to 75%.
- **Share of dialysis sessions using multiple-use dialysers (industry estimate)?** Over 60%.
- **How does the US FDA treat reprocessors of single-use devices?** As manufacturers, with the same requirements.
- **Which hospital law does the DGHS letter cite?** The Clinical Establishments (Registration and Regulation) Act, 2010.

## Prelims practice question

Consider the following laws:
1. Drugs and Cosmetics Act, 1940
2. Clinical Establishments (Registration and Regulation) Act, 2010
3. Consumer Protection Act, 2019
Which of the above were cited by the DGHS in its October 2026 letter banning reuse of single-use medical devices?

(a) 1 only
(b) 1 and 2 only
(c) 2 and 3 only
(d) 1, 2 and 3

Answer: (b) 1 and 2 only. The letter cited the Drugs and Cosmetics Act, 1940, the Medical Devices Rules, 2017 made under it, and the Clinical Establishments Act, 2010, along with infection control and biomedical waste provisions. The Consumer Protection Act, 2019 was not among the laws cited.

## UPSC previous-year questions this connects to

- UPSC Mains 2024, GS2: In a crucial domain like the public healthcare system the Indian State should play a vital role to contain the adverse impact of marketisation of the system. Suggest some measures through which the State can enhance the reach of public healthcare at the grassroots level. (https://upsc.help/pyq/q174-crucial-domain-like-public-healthcare-system-indian/)
  How to use this story in the answer: Use the 2026 single-use device ban to show the State regulating market-driven practices in private healthcare, and the cost trade-offs such regulation creates.
- UPSC Mains 2015, GS2: To achieve the desired objectives, it is necessary to ensure that the regulatory institutions remain independent and autonomous. Discuss in the light of experiences in the recent past. (https://upsc.help/pyq/q304-achieve-desired-objectives-necessary-ensure-regulatory-institutions/)
- UPSC Mains 2015, GS2: Public health system has limitation in providing universal health coverage. Do you think that private sector can help in bridging the gap? What other viable alternatives do you suggest? (https://upsc.help/pyq/q173-public-health-system-has-limitation-providing-universal/)

## Mains practice question

The ban on reusing single-use medical devices pits patient safety against the cost of care. Discuss, and suggest a regulatory approach that can serve both. (150 words)

### Model answer

On 16 October 2026 the DGHS banned reuse of single-use medical devices in all public and private facilities, citing infection risk and overcharging.

## Case for the ban
- Risks of cross-infection (hepatitis B, C, HIV), malfunction and complications.
- Patients or government schemes were sometimes charged full price for reused devices.
- Device makers' body AiMeD says such devices are not necessarily validated for reuse.

## Cost concerns
- Hospital groups (AHPI, NATHEALTH) warn of 25% to 75% higher costs for complex procedures.
- Over 60% of dialysis sessions use multiple-use dialysers; the PM National Dialysis Programme allows same-patient reuse under conditions.
- More medical waste and out-of-pocket spending.

## A balanced approach
- National classification of devices by reusability, so labels are not left to manufacturers alone.
- Reprocessing only in approved facilities, as the US FDA does by treating reprocessors as manufacturers.
- Caps on reuse, audits, patient consent, transparent billing and traceability.
- Domestic manufacturing to cut device prices.

Regulated reprocessing can protect patients without pricing them out of care.

## The basics

## Why this matters

Catheters, dialysers and surgical staplers are often labelled 'single use', yet some Indian hospitals have sterilised and reused them. On 16 October 2026, the Directorate General of Health Services (DGHS) told all public and private facilities to stop.

## Who regulates medical devices

Medical devices are regulated under the Drugs and Cosmetics Act, 1940 through the Medical Devices Rules, 2017, administered by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs Controller General of India. The Rules sort devices into four risk classes and require manufacturers to label single-use devices. See Medical Devices Rules, 2017.

## What the DGHS letter says

The letter went to State and Union Territory health secretaries and directors of health services, the Drugs Controller General of India and State drug controllers. It said single-use devices were being sterilised and reused in some private and corporate hospitals, especially in cardiology, nephrology, oncology, cardiothoracic and vascular surgery, and neurosurgery, and that patients or government schemes were sometimes charged the full price. Facilities must follow the original manufacturer's instructions. The letter cites the Drugs and Cosmetics Act, the 2017 Rules and the Clinical Establishments Act, 2010.

## Why reuse is risky, and why it happens

Reprocessing means cleaning, disinfecting, testing and sterilising a used device. Done badly, it can leave biological material behind, cause cross-infection such as hepatitis B, hepatitis C or HIV, or let a device fail mid-procedure. These are part of the wider problem of Hospital-acquired infections. Reuse persists partly because devices are costly; a government affidavit in the Supreme Court said mark-ups on hospital consumables could range from 100% to 1,000% or more.

## Who decides what is safe?

Manufacturers decide whether to label a device single-use, and they gain when hospitals buy new ones. Several countries therefore allow regulated reprocessing: the US Food and Drug Administration treats reprocessors as manufacturers, with the same duties. The explainer notes that India has historically lacked consistent reprocessing protocols, tracking and record-keeping. That gap is the subject of Regulated reprocessing of devices.

## Sources

- https://superkalam.com/current-affairs/20-11-2026/single-use-medical-devices-ban-on-reuse-and-who-decides-what-is-safe-pg-ii-1b59efd7-bd75-44d3-a7ae-ee1a3a4d8c0f
- https://theprint.in/india/dghs-flags-reuse-of-single-use-medical-devices-warns-of-infection-risks-and-possible-overcharging/3079866/
- https://thesouthfirst.com/health/centre-bans-reuse-of-single-use-medical-devices-doctors-warn-of-higher-treatment-costs/
- https://medicalbuyer.co.in/hospitals-push-back-on-single-use-device-ban-seek-regulated-reuse/
- https://www.gktoday.in/centre-bans-reuse-of-single-use-medical-devices/
